Heparin Sodium Panpharma

Heparin Sodium Panpharma is a pharmaceutical product containing the active ingredient heparin sodium. It is supplied in an injectable form for intravenous or subcutaneous administration, though specific strength and dosage form are not disclosed. Classified as an anticoagulant and antithrombotic, it works by enhancing antithrombin III activity to inhibit clotting factors. The product is marketed in the European Union and requires a prescription for clinical use.

Heparin Sodium Panpharma is indicated for several antithrombotic applications where rapid anticoagulation is required. It is commonly employed in hospital settings to prevent and treat clot‑related conditions.

- Prevention and treatment of venous thromboembolism, including deep‑vein thrombosis and pulmonary embolism. - Prophylaxis of deep vein thrombosis in surgical patients or those with limited mobility. - Anticoagulation during cardiac surgery, cardiopulmonary bypass, and extracorporeal dialysis procedures. - Management of clot formation in indwelling catheters and vascular access devices. - Adjunct therapy in acute coronary syndromes when rapid anticoagulation is needed.

Adverse reactions to Heparin Sodium Panpharma vary in frequency and severity, ranging from mild laboratory changes to rare but serious complications.

Common: - Minor bleeding at injection sites or from mucous membranes. - Small decreases in platelet count without clinical symptoms. - Transient elevation of liver enzymes detected on routine labs. - Localized bruising or hematoma formation around the injection area.

Serious: - Heparin‑induced thrombocytopenia (HIT) with paradoxical clot formation. - Major hemorrhage affecting internal organs or central nervous system. - Spontaneous spinal or epidural hematoma leading to neurologic deficits. - Severe allergic reactions such as anaphylaxis or angioedema.

Before prescribing Heparin Sodium Panpharma, clinicians should evaluate patient‑specific factors and monitor for conditions that increase bleeding risk.

- History of heparin‑induced thrombocytopenia or known hypersensitivity to heparin. - Active bleeding, recent intracranial surgery, or uncontrolled hypertension. - Severe liver disease or marked thrombocytopenia (platelet count <50 × 10⁹/L). - Concomitant use of other anticoagulants, antiplatelet agents, or thrombolytics. - Pregnancy (category B) – benefits must outweigh potential fetal risk. - Renal impairment requiring dose adjustment and close laboratory monitoring.

Heparin Sodium Panpharma may interact with other medicines, altering anticoagulant effect or increasing bleeding risk; careful assessment is essential.

Avoid: - Concurrent use with direct thrombin inhibitors (e.g., dabigatran) or factor Xa inhibitors (e.g., rivaroxaban, apixaban). - High‑dose aspirin or other non‑steroidal anti‑inflammatory drugs (NSAIDs) that impair platelet function. - Systemic fibrinolytic agents such as alteplase or streptokinase.

Use with caution: - Warfarin or other vitamin K antagonists, especially during initiation of heparin therapy. - Glycoprotein IIb/IIIa inhibitors used in interventional cardiology. - Certain antibiotics (e.g., vancomycin, cefoperazone) that may potentiate anticoagulant activity.